Skip to Content

AngioGenex Inc AGGX Stock Quote

| Rating as of


Morningstar‘s Stock Analysis AGGX

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics AGGX

Company Profile AGGX

Business Description

AngioGenex Inc is a United States-based biopharmaceutical company. It is dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer and macular degeneration. Its lead drug candidates include AGX51 and several other proprietary small molecules that have shown specific activity in various animal models of various cancers and macular degeneration. Further, it also focuses on developing Id-inhibitor drugs to treat cancer and macular degeneration. Geographically, the activities are carried out through the region of the United States.

425 Madison Avenue, Suite 902
New York, NY, 10017
T +1 347 468-6799
Industry Biotechnology
Most Recent Earnings Jun 30, 2019
Fiscal Year End Dec 31, 2019